Adial Pharmaceuticals has acquired Azora Therapeutics, gaining its lead drug candidate AT177, a colon-targeted treatment for ulcerative colitis designed to minimize systemic exposure and safety risks. Concurrently, Adial secured up to $64 million in private financing, including an initial $32 million upfront, to fund clinical development milestones, including Phase 1 trials planned for mid-2027. This acquisition and financing position Adial to advance a potentially best-in-class therapy addressing a significant unmet medical need in ulcerative colitis. The company also appointed Dr. Wendy Young to its board to support growth and drug development expertise.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
